Nanoparticle mediated alteration of EMT dynamics: an approach to modulate cancer therapeutics

Sen, Plaboni; Saha, Muktashree; Ghosh, Siddhartha Sankar

doi:10.1039/d0ma00455c

Cited by 12 publications

(6 citation statements)

References 125 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surface molecules expressed in diseased cells, proteins, sugars, or lipids contained in organs, molecules present in the microenvironment of the diseased cell (or secreted by tumor cells), and also the physicochemical environment surrounding them, may be the target substrate [15]. tibodies, aptamers, and proteins, polysaccharides, nucleic acids, and small molecules [36]. In two general ways, NPs with this ligand function.…”

Section: Active Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

Breast cancer remains one of the world’s most dangerous diseases because of the difficulty of finding cost-effective and specific targets for effective and efficient treatment methods. The biodegradability and biocompatibility properties of chitosan-based nanoparticles (ChNPs) have good prospects for targeted drug delivery systems. ChNPs can transfer various antitumor drugs to targeted sites via passive and active targeting pathways. The modification of ChNPs has attracted the researcher to the loading of drugs to targeted cancer cells. The objective of our review was to summarize and discuss the modification in ChNPs in delivering anticancer drugs against breast cancer cells from published papers recorded in Scopus, PubMed, and Google Scholar. In order to improve cellular uptake, drug accumulation, cytotoxicity, and selectivity, we examined different kinds of modification of ChNPs. Notably, these forms of ChNPs use the characteristics of the enhanced permeability and retention (EPR) effect as a proper parameter and different biological ligands, such as proteins, peptides, monoclonal antibodies, and small particles. In addition, as a targeted delivery system, ChNPs provided and significantly improved the delivery of drugs into specific breast cancer cells (MDA-MB-231, 4T1 cells, SK-BR-3, MCF-7, T47D). In conclusion, a promising technique is presented for increasing the efficacy, selectivity, and effectiveness of candidate drug carriers in the treatment of breast cancer.

show abstract

Section: Active Targetingmentioning

confidence: 99%

“…For this purpose, various types of ligands have been used, including monoclonal antibodies, aptamers, and proteins, polysaccharides, nucleic acids, and small molecules [ 36 ]. In two general ways, NPs with this ligand function.…”

Section: Biological Ligands For Nanoparticle Drug Delivery Systemsmentioning

confidence: 99%

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nanoparticles are valuable drug-delivering agents due to their small size, biocompatibilities and biodegradability properties, functionalization, and their enhanced permeability and retention (EPR) effect. Furthermore, depending on their physico-chemical and structural properties nanomaterials possess the ability to inhibit EMT [ 89 ].…”

Section: Emt As a New Target?mentioning

confidence: 99%

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities

et al. 2021

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lack of diagnosis. The effectiveness of PDAC therapies is challenged by the early and widespread metastasis. Epithelial to mesenchymal transition (EMT) is a major driver of cancer progression and metastasis. This process allows cancer cells to gain invasive properties by switching their phenotype from epithelial to mesenchymal. The importance of EMT has been largely described in PDAC, and its importance is notably highlighted by the two major subtypes found in PDAC: the classical epithelial and the quasi-mesenchymal subtypes. Quasi-mesenchymal subtypes have been associated with a poorer prognosis. EMT has also been associated with resistance to treatments such as chemotherapy and immunotherapy. EMT is associated with several key molecular markers both epithelial and mesenchymal. Those markers might be helpful as a biomarker in PDAC diagnosis. EMT might becoming a key new target of interest for the treatment PDAC. In this review, we describe the role of EMT in PDAC, its contribution in diagnosis, in the orientation and treatment follow-up. We also discuss the putative role of EMT as a new therapeutic target in the management of PDAC.

show abstract

“…Use of nanotechnology is a promising approach to develop more specific, less toxic cancer therapies. An emerging concept in cancer nanotechnology is harnessing the intrinsic cytotoxicity of nanoparticles to modulate the dynamics of EMT [19]. Drug-free, inorganic nanomaterials composed of gold [20], gadolinium [21], or silver [22] may specifically target the EMT cancer state.…”

Section: Introductionmentioning

confidence: 99%

Low Doses of Silver Nanoparticles Selectively Induce Lipid Peroxidation and Proteotoxic Stress in Mesenchymal Subtypes of Triple-Negative Breast Cancer

Snyder

Rohde

Fahrenholtz

et al. 2021

Cancers

View full text Add to dashboard Cite

Molecular profiling of tumors shows that triple-negative breast cancer (TNBC) can be stratified into mesenchymal (claudin-low breast cancer; CLBC) and epithelial subtypes (basal-like breast cancer; BLBC). Subtypes differ in underlying genetics and in response to therapeutics. Several reports indicate that therapeutic strategies that induce lipid peroxidation or proteotoxicity may be particularly effective for various cancers with a mesenchymal phenotype such as CLBC, for which no specific treatment regimens exist and outcomes are poor. We hypothesized that silver nanoparticles (AgNPs) can induce proteotoxic stress and cause lipid peroxidation to a greater extent in CLBC than in BLBC. We found that AgNPs were lethal to CLBCs at doses that had little effect on BLBCs and were non-toxic to normal breast epithelial cells. Analysis of mRNA profiles indicated that sensitivity to AgNPs correlated with expression of multiple CLBC-associated genes. There was no correlation between sensitivity to AgNPs and sensitivity to silver cations, uptake of AgNPs, or proliferation rate, indicating that there are other molecular factors driving sensitivity to AgNPs. Mechanistically, we found that the differences in sensitivity of CLBC and BLBC cells to AgNPs were driven by peroxidation of lipids, protein oxidation and aggregation, and subsequent proteotoxic stress and apoptotic signaling, which were induced in AgNP-treated CLBC cells, but not in BLBC cells. This study shows AgNPs are a specific treatment for CLBC and indicates that stratification of TNBC subtypes may lead to improved outcomes for other therapeutics with similar mechanisms of action.

show abstract

Nanoparticle mediated alteration of EMT dynamics: an approach to modulate cancer therapeutics

Abstract: Metastasis is the cause of approximately 90% of cancer-related morbidities and mortalities, which is accredited to the phenomenon of EMT (epithelial to mesenchymal transition). The pathological activation of EMT during...

Cited by 12 publications

References 125 publications

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment

Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities

Low Doses of Silver Nanoparticles Selectively Induce Lipid Peroxidation and Proteotoxic Stress in Mesenchymal Subtypes of Triple-Negative Breast Cancer

Contact Info

Product

Resources

About